Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 20/20 | 0.87 |
| ▸ | CCNT1 | O60563 | 19/20 | 0.87 |
| ▸ | CDK4 | P11802 | 19/20 | 0.87 |
| ▸ | CCND1 | P24385 | 19/20 | 0.87 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.65 |
| ▸ | CDK2 | P24941 | 7/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30450358 | 0.93 | CCNT1 (1.00) | CDK9CCNT1CDK4CCND1CCNA2 | |
| SCHEMBL23068002 | 0.93 | CCNT1 (1.00) | CDK9CCNT1CDK4CCND1CCNA2 | |
| SCHEMBL29788696 | 0.93 | CCNT1 (1.00) | CDK9CCNT1CDK4CCND1CCNA2 | |
| SCHEMBL29788683 | 0.79 | CCNT1 (1.00) | CDK9CCNT1CDK4CCND1CCNA2 | |
| SCHEMBL23068008 | 0.79 | CCNT1 (1.00) | CDK9CCNT1CDK4CCND1CCNA2 | |
| SCHEMBL23067971 | 0.79 | CCNT1 (1.00) | CDK9CCNT1CDK4CCND1CCNA2 | |
| SCHEMBL23068004 | 0.79 | CCNT1 (1.00) | CDK9CCNT1CDK4CCND1CCNA2 | |
| SCHEMBL29788700 | 0.79 | CCNT1 (1.00) | CDK9CCNT1CDK4CCND1CCNA2 | |
| SCHEMBL29788720 | 0.79 | CCNT1 (1.00) | CDK9CCNT1CDK4CCND1CCNA2 | |
| SCHEMBL23068003 | 0.77 | CCNT1 (1.00) | CDK9CCNT1CDK4CCND1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK3, CDK9 | CDK9 3/4885CCNT1 40/4885CDK4 10/4885 |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK3, CDK9 | CDK9 3/4885CCNT1 40/4885CDK4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.